Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1253

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Journal Articles

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Blood (2020) 135 (24): 2182–2191.

https://doi.org/10.1182/blood.2019004710

Published: 2020

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan

Shohei Mizuno, MD PhD, Masamitsu Yanada, Koji Kawamura, Shingo Yano, MD PhD, Masayoshi Masuko, MD, Naoyuki Uchida, MD PhD, Yukiyasu Ozawa, MD PhD, Koji Iwato, Kazuteru Ohashi, MD PhD, Kazuhiro Ikegame, MD PhD, Sung-Won Kim, MD PhD, Masatsugu Tanaka, MD, Tetsuya Eto, MD PhD, Yoshinobu Kanda, MD PhD, Takahiro Fukuda, Yoshiko Atsuta, MD PhD, Akiyoshi Takami, MD

Blood (2019) 134 (Supplement_1): 2045.

https://doi.org/10.1182/blood-2019-122801

Published: 2019

Journal Articles

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Katia Beider, Valeria Voevoda, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Ivetta Danilesko, MD, Ania Hava Grushchenko-Polaq, Olivia Devillers, Idit Wolf, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 1989.

https://doi.org/10.1182/blood-2019-129619

Published: 2019

Journal Articles

Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Christopher D'Angelo, MD, Sailendharan Sudakaran, PhD, Peiman Hematti, MD, Fotis Asimakopoulos, PhDMBBChir,, Craig Augustine, MBA, Nasia Safdar, MD PhD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 4653.

https://doi.org/10.1182/blood-2019-123530

Published: 2019

Journal Articles

Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia

Malin S Nilsson, MSc, Alexander Hallner, PhD, Mats Brune, MD PhD, Staffan Nilsson, PhD, Fredrik B Thorén, PhD, Anna Martner, PhD, Kristoffer Hellstrand, MD PhD

Blood (2019) 134 (Supplement_1): 1318.

https://doi.org/10.1182/blood-2019-130345

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 1541.

https://doi.org/10.1182/blood-2019-127494

Published: 2019

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis

Nishi Shah, MBBS, MPH, Mohammad Kazemi, Stephen Zachary Peeke, MD, Lizamarie Bachier-rodriguez, R.Alejandro Sica, MD, Noah Kornblum, MD, Ira Braunschweig, MD, Aditi Shastri, MD, Amit Verma, MBBS, Ioannis Mantzaris, MD MS

Blood (2019) 134 (Supplement_1): 426.

https://doi.org/10.1182/blood-2019-123168

Published: 2019

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Zachary D. Epstein-Peterson, MD, Barbara Spitzer, MD, Joseph McCarter, PhD, Erin McGovern, BA, Ross L. Levine, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 2708.

https://doi.org/10.1182/blood-2019-123400

Published: 2019

Journal Articles

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 2622.

https://doi.org/10.1182/blood-2019-125342

Published: 2019

Journal Articles

Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype

Sharad Khurana, MDMSc, Michael G. Heckman, Jordan Cochuyt, Fiona E. Craig, MBBS, Zaid Abdel Rahman, MD, Patricia Greipp, DO, Lisa Z. Sproat, MD, Mark Litzow, MD, James M. Foran, MD, Liuyan Jiang

Blood (2019) 134 (Supplement_1): 5210.

https://doi.org/10.1182/blood-2019-123286

Published: 2019

Journal Articles

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Joanne L C Tan, MBBS, Eric Wong, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Radha Ramanan, MBBS, Andrew B M Lim, David Ritchie, MD PhD

Blood (2019) 134 (Supplement_1): 5662.

https://doi.org/10.1182/blood-2019-122363

Published: 2019

Journal Articles

Comparison of the DONOR Lymphocyte Infusion and Second Allogeneic STEM-CELL Transplantation in the Treatment of First Hematological Relapse after Allogeneic STEM-CELL Transplantation in Adults with ACUTE Leukemia

Haluk Demiroglu, MDPROF., Elifcan Aladag, MD, Nelson J. Chao, MD, Yahya Buyukasik, MD, Hakan Goker, MDPROF.

Blood (2019) 134 (Supplement_1): 5698.

https://doi.org/10.1182/blood-2019-121599

Published: 2019

Journal Articles

Metabolic Syndrome Post Allogeneic STEM CELL Transplantation in Adult Patients Is NOT an Uncommon Complication. a Single Center Experience

Panayotis Kaloyannidis, Deia Awami, MD, Solaf Kanfar, MD, Zahra Abdrabalamir Alshammasi, MD, Mohammed Darweesh, MD, Enas Mutahar, MD, Ahmed Bahrani, MD, Rabab Attas, Heba Raslan, MD, John Apostolidis, MD, Khalid Ahmed Al-Anazi, MD, Hani Al Hashmi, MD

Blood (2019) 134 (Supplement_1): 5695.

https://doi.org/10.1182/blood-2019-129045

Published: 2019

NARROW

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Comparison of the DONOR Lymphocyte Infusion and Second Allogeneic STEM-CELL Transplantation in the Treatment of First Hematological Relapse after Allogeneic STEM-CELL Transplantation in Adults with ACUTE Leukemia

Metabolic Syndrome Post Allogeneic STEM CELL Transplantation in Adult Patients Is NOT an Uncommon Complication. a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only